This marked the first time a GLP-1 medication demonstrated improvement in fibrosis itself, a key milestone in treating a disease that until recently had almost no pharmacologic options [9]
Despite revenue potential, extreme care must be taken to avoid creating more new patients for GLP-1 side effects than treating existing ones
The GLP-1R interacts with structurally related peptide hormone ligands, such as glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), parathyroid hormone, etc
Notably, all participants started with very high ICP (mean ~ 30.6 cmCSF), so a 56 cmCSF reduction was felt to be clinically meaningful (roughly 1520% reduction)
Combination of Glucagon-Like Peptide 1 Receptor Agonist and Thiazolidinedione for Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes
You can see the bacteria breaking into the cells and nom-nomming all the goodies